Ablynx Overview
- Founded
-
2001

- Status
-
Acquired/Merged
- Employees
-
438

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$4.72B
Ablynx General Information
Description
Manufacturer of biopharmaceutical products created to offer proteins based therapeutics for treatment of inflammation, hematology, immuno-oncology, oncology and respiratory diseases. The company's biopharmaceutical products comprises of their patented product named, Nanobodies that is a therapeutic proteins based on single-chain antibody fragments that combine the benefits of drugs based on conventional antibodies and small chemical molecules, enabling patients avail various therapeutic and new drugs that can make a clear difference to society.
Contact Information
Website
www.ablynx.com
Formerly Known As
MatchX
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Office
- Technologiepark 21
- 9052 Ghent
- Belgium
Ablynx Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
14. Merger/Acquisition | 14-May-2018 | $4.72B | 00000 | 00.000 | Completed | Profitable |
13. Merger/Acquisition | 01-Dec-2017 | 00.000 | 00.000 | Cancelled | Profitable | |
12. 2PO | 25-Oct-2017 | 00000 | 00000 | 00.00 | Completed | Profitable |
11. PIPE | 04-Oct-2017 | 00000 | Completed | Profitable | ||
10. Secondary Transaction - Open Market | 03-Nov-2016 | 00000 | Completed | Profitable | ||
9. PIPE | 01-Jun-2016 | 000.00 | 00000 | Completed | Profitable | |
8. Secondary Transaction - Open Market | 18-Oct-2013 | 00.000 | 00000 | Completed | Generating Revenue | |
7. 2PO | 16-Mar-2010 | 000.00 | 00000 | Completed | Generating Revenue | |
6. IPO | 07-Nov-2007 | $108M | $196M | Completed | Generating Revenue | |
5. Later Stage VC (Series C) | 23-Aug-2006 | $51.2M | $88.2M | Completed | Generating Revenue |
Ablynx Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Manufacturer of biopharmaceutical products created to offer proteins based therapeutics for treatment of inflammation, h
Biotechnology
Ghent, Belgium
438
As of 2017
00000
0.000
0000-00-00
000000&0
00000
Ablynx Competitors (52)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Arrowhead Pharmaceuticals | Corporation | Pasadena, CA | 000 | 00.000 | 000000 - 000 | 00.000 |
00000 000000000000 | Corporation | Pasadena, CA | 0 | 000.00 | 000000000 | 000.00 |
000 000000000000 | Formerly PE-Backed | High Point, NC | 00 | 00000 | 000000000 | |
00000 | Formerly VC-backed | Cambridge, United Kingdom | 000 | 00000 | 000000&0 | 00000 |
000000000 00000000 | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 00000 | 0000000000 0 | 00000 |
Ablynx Patents
Ablynx Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-4126971-A1 | Method for the production and purification of multivalent immunoglobulin single variable domains | Pending | 30-Mar-2020 | 000000000 | |
AU-2021246890-A1 | Method for the production and purification of multivalent immunoglobulin single variable domains | Pending | 30-Mar-2020 | 000000000 | |
CA-3175873-A1 | Method for the production and purification of multivalent immunoglobulin single variable domains | Pending | 30-Mar-2020 | 000000000 | |
EP-3636657-A1 | Chromatography-free antibody purification method | Inactive | 08-Oct-2018 | 00000000 | 00 |
US-20210371457-A1 | Chromatography-free antibody purification method | Pending | 08-Oct-2018 | C07K1/34 |
Ablynx Board Members (10)
Name | Representing | Role | Since |
---|---|---|---|
Bo Jesper Hansen Ph.D | Self | Board Member | 000 0000 |
Ablynx Signals
Ablynx Former Investors (10)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Abingworth | Venture Capital | Minority | 000 0000 | 000000 0 | |
Alta Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Fidelity Management & Research | Venture Capital | Minority | 000 0000 | 000000 0 | |
Gilde Healthcare | Venture Capital | Minority | 000 0000 | 000000 0 | |
Gimv | PE/Buyout | Minority | 000 0000 | 000000 0 |